Key Trends and Insights into the Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the chemotherapy-induced nausea and vomiting (cinv) market size evolved in recent years?
The market size for chemotherapy-induced nausea and vomiting (CINV) has seen a significant surge in the preceding years. Expected to rise from $2.92 billion in 2024, it will reach $3.15 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.9%. The growth observed in the historical period is largely due to factors such as increased utilization of chemotherapy, advanced antiemetic agents, evolving clinical guidelines, and enhanced patient advocacy.
What are the predictions for the chiplets market size in the coming years?
The market size for chemotherapy-induced nausea and vomiting (CINV) is projected to witness substantial expansion in the coming years, reaching $4.2 billion in 2029 with a 7.5% compound annual growth rate (CAGR). This noticeable growth in the forecast period can be credited to factors like tailored medication practices, advancements in antiemetic agents, the use of telehealth and remote monitoring, and health equity efforts. The forecast period will also see major trends like the utilization of combination antiemetic therapies, incorporation of supportive care services, deployment of digital health utilities, and the focus on survivorship care.
Get your chemotherapy-induced nausea and vomiting (cinv) market report here!
What key factors are fueling the growth of the chemotherapy-induced nausea and vomiting (cinv) market?
The rising incidence of cancer is anticipated to spur the expansion of the chemotherapy-induced nausea and vomiting (CINV) market. Cancer involves the unregulated growth and proliferation of certain cells within the body, and as the number of cancer cases continues to rise, there’s an increasing urgency to create more effective and precise anti-emetic treatments to relieve CINV, an unpleasant byproduct of chemotherapy. This amplified emphasis on managing CINV has catalyzed advancements in understanding its root causes and formulating innovative therapies. For example, the American Cancer Society (ACS), a non-profit volunteer health organization dedicated to eliminating cancer, estimated in January 2023 that there would be around 1.9 million new cancer cases (roughly 5,370 cases per day) and 609,820 cancer-related deaths (approximately 1,670 deaths each day) in the United States in 2023. Therefore, the growing incidence of cancer is set to be a key driver of the chemotherapy-induced nausea and vomiting (CINV) market. Positive regulatory initiatives are also anticipated to drive the growth of the chemotherapy-induced nausea and vomiting (CINV) market. These initiatives undertaken by regulating authorities involve the creation, enforcement, or upgrading of regulations. Such regulatory measures can be employed to enhance the prevention and control of chemotherapy-induced nausea and vomiting (CINV) by formulating and implementing guidelines. For instance, as per the U.S. Food and Drug Administration, in 2023, the CDER (Center for Drug Evaluation and Research, a segment of the U.S. Food and Drug Administration) approved 55 new drugs for treating chemotherapy-induced nausea and vomiting (CINV) in October 2024. Consequently, the rising favorable regulatory initiatives are contributing to the expansion of the chemotherapy-induced nausea and vomiting (CINV) market.
How is the global chemotherapy-induced nausea and vomiting (cinv) market divided into key segments?
The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Who are the key firms paving the way for growth in the chemotherapy-induced nausea and vomiting (cinv) market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Which trends are expected to transform the chemotherapy-induced nausea and vomiting (cinv) market?
Dominant firms in the market for chemotherapy-induced nausea and vomiting (CINV) are focusing on the innovation of new products, such as pre-set intravenous antiemetic, to secure a competitive edge. This fixed intravenous antiemetic denotes a set dosage of medicine given through an IV to alleviate or prevent nausea and vomiting, typically used in chemotherapy or post-operation situations. Take for example, Glenmark Pharmaceuticals Limited, an Indian pharmaceutical, generics, and OTC products producer, who, in January 2023, launched AKYNZEO I.V. in India – the country’s first fixed intravenous antiemetic combination aimed at preventing CINV. This product merges netupitant and palonosetron and targets both immediate and late stages of nausea and vomiting. It provides the ease of a single dose, heightened full response rates, and improved quality of life for those with cancer. Research indicates it is notably advantageous for patients undergoing highly emetogenic chemotherapy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031
What regions are contributing significantly to the growth of the chemotherapy-induced nausea and vomiting (cinv) market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
High Performance Liquid Chromatography Global Market Report 2024
High Performance Liquid Chromatography Global Market Report 2024
Gas Chromatography Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gas-chromatography-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
